Allogeneic stem cell transplantation utilizes adult stem cells from a matched donor to restore bone marrow and immune system in cancer patients who have received very high doses of chemotherapy and/or radiation therapy. It is an important treatment option for cancers such as leukemia and lymphoma where high-dose chemotherapy can eradicate the malignancy. The global Allogeneic stem cell transplantation market relies on transplantation of hematopoietic stem cells from a matched donor and special immunosuppressive therapy. The procedure allows replacement of malignant stem cells with healthy ones to restore normal blood cell production. It also helps in rebuilding the diseased immune system.
The global Allogeneic Stem Cell Transplantation Market is estimated to be valued at US$ 3.9 Bn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends driving the allogeneic stem cell transplantation market growth is rising incidence of cancer globally. According to WHO, cancer burden rose to 19.3 million cases and 10 million cancer deaths in 2020. It is among the leading causes of death worldwide. Countries are witnessing growing cancer prevalence due to aging population, changing lifestyle habits and others. Higher cancer rates fuel demand for treatment options such as stem cell transplantation wherein cancerous cells in bone marrow are replaced with healthy ones from donors. This provides hope for cure or prolonging lives to many cancer patients. Growing acceptance of stem cell therapy as an effective option for blood cancers and solid tumors are boosting prospects of the allogeneic stem cell transplantation market during the forecast period.
Threat of new entrants: The entry barriers in the allogeneic stem cell transplantation market are high due to high initial investment required for R&D, equipment, skilled workforce and certification from regulatory authorities.
Bargaining power of buyers: The bargaining power of buyers is moderate as the demand for allogeneic transplantation depends on the number of patients suffering from blood cancer, autoimmune diseases etc.
Bargaining power of suppliers: The bargaining power of suppliers is low as there are many suppliers for raw materials and consumables.
Threat of new substitutes: There is low threat from substitutes as allogeneic transplantation is a unique procedure currently performed to treat cancer and blood-related diseases.
Competitive rivalry: The competition is high among the major players operating in the market.
The Global Allogeneic Stem Cell Transplantation Market Demand is expected to witness high growth. The global Allogeneic Stem Cell Transplantation Market is estimated to be valued at US$ 3.9 Bn in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030.
Regional analysis: North America region holds the largest share in the allogeneic stem cell transplantation market due to high adoption rate of stem cell therapy and availability of advanced treatment facilities. The market in Asia Pacific region is projected to witness fastest growth over the forecast period owing to growing healthcare expenditure, rising cancer incidence and increasing patient pool in countries like China and India.
Key players: Key players operating in the allogeneic stem cell transplantation market are Wacker Neuson SE, Sany Heavy Industry Co. Ltd, Volvo Construction Equipment, Wirtgen Group, Caterpillar Inc., Atlas Copco, Terex Corporation, Zoomlion Heavy Industries Science & Technology Co Ltd, Fayat Group, BOMAG GmbH, and XCMG Co. Ltd. Wacker Neuson SE is one of the leading player providing innovative solutions for compact equipment.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it